Liver cirrhosis is characterized by a severe impairment of the growth hormone/insulin-like growth factor-1 (GH-IGF-1) axis, that is, acquired GH resistance. The condition of the GH-IGF-1 axis in the phase of chronic liver disease (CLD) preceding cirrhosis, however, remains uncertain. The origin of GH resistance during CLD is multifactorial, and to date, the liver functional mass is considered to play a major role. Although proinflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and IL-1beta, were found to be elevated in patients with CLD and were shown to induce a state of GH resistance in other disease models, their involvement in the pathogenesis of GH resistance during CLD has never been investigated. We characterized the GH-IGF-1 axis by analyzing the individual components of the axis (GH, IGF-1, IGF-binding protein-3 [IGFBP-3], acid-labile subunit [ALS]) and the corresponding ratios (GH/IGF-1, GH/IGFBP-3, and GH/ALS) and verified the links with circulating proinflammatory cytokines (TNF-alpha, IL-1beta, and IL-6), in 34 patients with CLD and 12 healthy controls. Evolution of CLD from chronic hepatitis (CH, n = 17) to cirrhosis (CIR, n = 17) was associated with a progressive increase of GH resistance indices (e.g., GH/IGF-1 ratio: controls 0.5 +/- 0.9, CH 15.9 +/- 31.2, p < 0.01 vs. controls; CIR 188.4 +/- 282.7 mU/nmol, p < 0.001 vs. CH and controls), indicating its onset also in the early stages of CLD. The progressive increase in GH resistance indices matched the increase of circulatory TNF-alpha (e.g., TNF-alpha vs. GH/IGF-1, r = 0.54, p < 0.001). A similar trend was found for IL-6 without reaching statistical significance (r = 0.23, p = 0.13). We found undetectable levels of IL-1beta in our sample of patients and controls. We conclude that proinflammatory cytokines play an important role in the pathogenesis of GH resistance in CLD, but TNF-alpha is a major factor. In addition, GH resistance is present in CLD from the early stages. These results could begin new therapeutic lines of attack in the management of CLD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/107999003321829944 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Size-specific clonidine-loaded liposomes: Advancing melanoma microenvironment suppression with safety and precision.
J Control Release
January 2025
Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; Furong Laboratory (Precision Medicine), Changsha 410008, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Central South University, Changsha 410008, China. Electronic address:
The immunosuppressive tumor microenvironment (TME) plays a crucial role in the progression and treatment resistance of melanoma. Modulating the TME is thus a key strategy for enhancing therapeutic outcomes. Recent studies have identified clonidine (CLD), an α2-adrenergic receptor agonist, as a promising agent that enhances T lymphocyte infiltration and reduces myeloid-derived suppressor cells within the TME, thereby promoting antitumor immune responses.
View Article and Find Full Text PDFUncovering the Differed Susceptibility of ( and ) to Fungicide Phenamacril: From Computational and Experimental Perspectives.
J Agric Food Chem
December 2024
Centre for Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao 999078, China.
and are two subtypes of (Fo), a pathogenic filamentous fungus. Phenamacril (PHA), a -specific fungicide that targets myosin I, exhibits significant hyphal growth inhibition in but shows weak resistance in , despite only two amino acid differences in the PHA-binding pocket of myosin I. In this study, we aim to elucidate the molecular basis for the differential sensitivity of myosin I variants (FoMyoI and FoMyoI) to phenamacril through computational methods and biochemical validation.
View Article and Find Full Text PDFStard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity.
Hepatology
December 2024
Department of Cell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), CSIC; Unidad Asociada IMIM/IIBB-CSIC, Barcelona, Spain.
Article Synopsis
- - Cholestatic liver diseases (CLD) cause damage to the liver cells and can lead to fibrosis and cirrhosis due to bile acid accumulation, with STARD1 playing a potential role in this process.
- - Research found that patients with primary biliary cholangitis had higher STARD1 levels, and mice lacking STARD1 specifically in liver cells were more resistant to liver damage and inflammation associated with bile duct blockage.
- - The study suggests that targeting STARD1 could be a promising approach for treating cholestatic liver injury, as it appears to influence bile acid levels and oxidative stress in liver cells.
Systematic characterization of the bZIP gene family in Colletotrichum siamense and functional analysis of three family members.
Int J Biol Macromol
December 2024
Sanya Institute of Breeding and Multiplication, School of Tropical Agriculture and Forestry, Hainan University, Haikou 570228, China. Electronic address:
Article Synopsis
- * Researchers identified 25 bZIP genes in the C. siamense genome, classifying them into 11 evolutionary groups based on shared gene structures and protein motifs, and identified potential functional interactions among these proteins.
- * The expression of 23 of these bZIP genes was responsive to antifungal agents, leading to the conclusion that specific bZIP genes play key roles in regulating growth, fungicide resistance, and pathogenicity in C. siamense, laying the groundwork for future studies
Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the first four years of the COVID-19 pandemic.
EBioMedicine
December 2024
The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia. Electronic address:
Article Synopsis
- Ongoing research is essential for tracking and understanding the emergence of new SARS-CoV-2 variants, particularly as diagnostic testing declines in Australia during the COVID-19 pandemic.
- In 2023, collaborations with pathology and genomics teams allowed for the monitoring of SARS-CoV-2 variants in New South Wales through various methods, including viral culture and analysis of immune responses from a large pool of blood donations.
- Findings indicated that while existing antibodies generally neutralized many variants, specific mutations in emerging strains, particularly JN.1, suggested future challenges in controlling their spread due to enhanced transmissibility.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!